Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors
MBZ is safe and tolerable in treating refractory or progressive pediatric brain tumors, with doses up to 2500 mg/m<sup>2</sup>/day. There was limited evidence of single-agent efficacy.
Authors
- Philippe Phan (ORCID: https://orcid.org/0000-0003-0270-6210)
- Eric H. Raabe (ORCID: https://orcid.org/0000-0002-9368-7037)
- Kenneth J. Cohen (ORCID: https://orcid.org/0000-0001-9193-9344)
- Gregory J. Riggins (ORCID: https://orcid.org/0000-0002-4538-0436)
- Michael A. Koldobskiy (ORCID: https://orcid.org/0000-0002-2980-6644)
- Stacie Stapleton (ORCID: https://orcid.org/0000-0001-6459-4360)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Johns Hopkins All Children's Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Neuro-Oncology Practice
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1093/nop/npaf060
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63